BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Emerging Biotech

CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS

CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...

September 22, 2025 | News

EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications

EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through it...

September 18, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

September 16, 2025 | News

Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer

Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinica...

September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

September 15, 2025 | News

YolTech Raises $45 Million in Series B Funding to Propel In Vivo Gene-Editing Therapies

YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $...

September 12, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

iRegene Secures Over RMB 300 Million in Landmark Series B+ Financing to Advance First-in-Class iPSC Cell Therapies

iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, ...

September 10, 2025 | News

Epigenic Therapeutics Raises $60 Million in Series B Financing to Advance Epigenetic Medicine Pipeline

Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series ...

September 09, 2025 | News

Sirnaomics Secures HKD 138 Million Strategic Investment from Bloomage Biotech

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, announced that it has entered into a ...

September 09, 2025 | News

Servier Acquires Kaerus Bioscience’s KER-0193 in Deal Worth Up to $450M

Servier, an independent international pharmaceutical group governed by a foundation, announced that it has entered into a definitive agreement with Kaerus ...

September 09, 2025 | News

Huadong Medicine Reports Promising Phase I Results for Novel ROR1-Targeting ADC HDM2005 in Lymphoma

Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") announced positive preliminary results from a Phase I study of HDM2005, an...

September 08, 2025 | News

Stay Connected